Physician profile
Carlos E Ramirez
NPI 1982629309
$33,002.07
in general payments reported to CMS, 2019-2025
45 companies · $4,814 in 2025
The $4,814 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,235 · 2020: $3,169 · 2021: $3,797 · 2022: $5,190 · 2023: $5,827 · 2024: $4,970 · 2025: $4,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,404.41 |
| Education | $206.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,931.44 | 2019-2025 | |
| Amgen INC. | $5,442.69 | 2019-2025 | Otezla, Otezla, Tavneos |
| Ucb, INC. | $2,647.43 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $2,130.38 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $1,860.73 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $1,431.01 | 2019-2025 | Tremfya |
| Pfizer INC. | $1,347.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,340.98 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $1,183.86 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $1,009.03 | 2019-2025 | Orencia, Sotyktu |
| Genzyme Corporation | $770.13 | 2019-2024 | |
| Horizon Therapeutics Plc | $708.04 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $696.86 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $598.08 | 2022-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $402.06 | 2019 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.